Company Overview
Daré Bioscience, Inc. operates within the biotechnology industry, focusing on the development of therapeutic solutions for specific conditions including contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company's product portfolio currently includes XACIATO, a lincosamide antibacterial gel indicated for the treatment of bacterial vaginosis, alongside ongoing development efforts for other therapeutic areas. This biotechnology firm is classified under the broader healthcare sector, which encompasses the discovery, development, and commercialization of medical products and services. As of the latest data, the company maintains a market capitalization of $22.57M and employs 21 individuals to execute its operational strategy. The reported annual revenue for the trailing twelve months is -$57,130, indicating that the company is currently operating at a loss on a commercial scale rather than generating positive cash inflows from sales. These financial figures suggest that Daré Bioscience is in a pre-profitability stage, likely investing heavily in research and development to bring future therapies to market rather than relying on established revenue streams. The small market cap and negative revenue position highlight the company's status as a micro-cap entity with a significant portion of its value derived from intellectual property potential rather than current financial performance.
Financial Health
The financial statements for Daré Bioscience, Inc. reveal a revenue of -$57,130 for the trailing twelve months, accompanied by a net income of -$17,463,954 and an EBITDA of -$16,362,804. The substantial gap between the negligible revenue figure and the massive negative net income indicates a cost structure dominated by high operating expenses, likely related to R&D activities and overhead costs that far exceed current sales. The company generated free cash flow of -$938,184, which reflects a consumption of cash reserves necessary to sustain its operations and development programs without external financing. Regarding profitability metrics, the gross margin stands at 0.0%, while the operating margin is reported at -162340.8% and the profit margin is 0.0%, figures that underscore the lack of positive gross sales relative to the high fixed costs incurred. The balance sheet shows the company holds $23.08M in cash against $2.93M in debt, resulting in a debt-to-equity ratio of 102.61. Despite the high leverage ratio, the absolute amount of debt is relatively small compared to the available cash, suggesting the company has sufficient liquidity to meet its obligations without immediate distress. The current ratio is 1.18, indicating that the company possesses 1.18 dollars in current assets for every dollar of current liabilities, which provides a baseline level of short-term liquidity to cover immediate obligations. Return on Equity is -2543.1% and Return on Assets is -44.7%, metrics that reveal the company is currently destroying value per share and per asset unit due to the heavy losses incurred during its development phase.
Valuation Assessment
Valuation multiples for Daré Bioscience, Inc. present unique characteristics typical of pre-revenue biotechnology companies, with a trailing P/E ratio of N/A and a forward P/E of 1.70. The discrepancy between a non-existent trailing P/E and a low forward P/E implies that the market is pricing the stock based on anticipated future earnings once the company achieves profitability, rather than current financial performance. The price-to-book ratio is 7.56, suggesting that the market values the company's equity at a significant premium over its net asset value, reflecting the intangible value of its intellectual property and pipeline. Alternative valuation metrics include a price-to-sales ratio of -395.02 and an EV/EBITDA of -0.09, which indicate that traditional valuation models are distorted by the negative earnings and revenue structure common in early-stage development firms. The stock has a 52-week high of $9.19 and a 52-week low of $1.27, and given the current market capitalization of $22.57M, the price is situated within a wide volatility band where the upper bound represents a nearly eightfold increase over the lower bound. The beta value is 0.98, indicating that the stock's price volatility moves in tandem with the broader market, exhibiting neither significant amplification nor dampening of market movements.
Growth & Income
Daré Bioscience, Inc. reported a revenue growth of -94.6% year-over-year, while earnings growth is listed as N/A due to the absence of prior comparable positive earnings. The negative revenue growth combined with negative earnings growth implies that the company is currently contracting in terms of top-line sales while simultaneously expanding its losses, a pattern consistent with a firm transitioning from R&D investment to commercialization. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means that instead of distributing income to shareholders, the company retains all earnings to fund its research and development initiatives. Consequently, the overall growth and income profile is characterized by a complete reinvestment of resources into future product development rather than providing current income generation for investors.